BioSpace News Archive

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced positive interim data from its ongoing Phase 3 FURI and CARES studies.

Ginkgo Bioworks, the leading horizontal platform for cell programming, announced plans to significantly expand its platform capabilities in agricultural biologicals, from discovery to field.

Salarius Pharmaceuticals, Inc. today announced that it has entered into definitive agreements with several institutional investors for the purchase of 9,339,436 shares of its common stock, at a purchase price per share of $0.25, for gross proceeds of approximately $2.3 million, in a registered direct offering.

Assertio Holdings, Inc. today announced that it will release first quarter 2022 financial results on Monday, May 9, 2022, after the close of markets.

CEL-SCI Corporation announced that two abstracts related to CEL-SCI’s pivotal Phase 3 head and neck cancer clinical trial were accepted at the American Society of Clinical Oncology meeting being held June 3-7, 2022 in Chicago, IL.

Coya Therapeutics, Inc. (“Coya”), a privately held clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced its participation in the annual Neuro & Ophthalmology Conference hosted by B. Riley Securities, a leading full-service investment bank and subsidiary of B. Riley Financial, on April 27-28th 2022.

Royal Philips, a global leader in health technology, announced that its subsidiary Philips Respironics is notifying customers of its V60/V60 Plus and V680 ventilators about a potential issue with the electrical circuit in these ventilators that controls the 35V power supply to the ventilator and alarm.

Increasing prevalence of hair loss among individuals across the globe, rising demand for efficient treatment modalities, and growing number of clinical trials are some key factors expected to drive market growth.

The industry analysis report is considered a valuable source of information about the global Breast Localization Wire industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years

Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, Portugal between April 23 and 26, 2022.